Default company panoramic image
216b6575 121a 4cdf a6e8 d97b4fefc9be

RD Antibodies

Funding for the launch of a set of novel highly predictive in vitro diagnostic tests directed at the early identification of sepsis

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Las Vegas, NV, USA
  • Currency USD
  • Founded August 1986
  • Website

Company Summary

Sepsis and septicemia make up 2% of the patient population, ~800,000 in the US, but 17% of the deaths according to the CDC. The current standard of care which is the Procalcitonin (PCT) test lacks sensitivity, cultures take 3 days, and MDx tests miss the mark. RD Antibodies has solved the mystery of sepsis, identified key markers that identify stage, and monitor patients, and is launching the first generation test to help solve this problem.


  • Default avatar
    Robert Webber, Ph.D.
    President and CEO

    Ph.D. University of California Berkeley. Dr. Webber founded RD Antibodies over 20 years ago to design specialty antibodies. He has single-handedly identified and driven these new sepsis markers completing 3 NIH funded clinical trials. The ground breaking results of these and his current clinical trial should lead to a De Novo PMA filing with FDA. RD Antibodies is nearing completion of a ISO 13485 designation and is preparing to launch the pro

  • Default avatar
    Richard Sweet, M.D.
    Chief Medical Officer

    Medical Advisor and Company Investor. Dr. Sweet serves as an Associate Professor on the faculty of the University of California San Francisco (UCSF) Medical School. Dr. Sweet is board certified in internal medicine, nephrology, and critical care medicine. He has extensive clinical, medical leadership and business experience and is also Chief Medical Officer at Hemo Therapeutics, Inc.

  • Default avatar
    Guy Henshaw, MBA

    Financial Expert. Commercial banker, investment manager, and management counsel most of my career. He has sat on the boards of banks, software companies, and bio-tech firms. Currently sits on investment committees of four public and private organizations managing over $1.5 billion in assets. Previously, Chairman, President, CEO, and CFO of several companies Helps start up companies stay focused and guides them to growth to merger or sale.

  • Default avatar
    David A. Hagebush
    Marketing & Investment Consultant

    Multiple start-up entrepreneur with 25 + years of in vitro diagnostic (IVD), life science, and medical device product development, project management, and product marketing experience.

    Technology inventor with a significant background in life sciences and IVD workflow analysis developing ISO systems, and supporting documentation and ushering CLIA laboratories, IVD systems, and medical device products through FDA / regulatory approval processe

  • Default avatar
    Judd Landsberg, M.D.

    Associate Clinical Professor of Medicine, Director, Medical Intensive Care Unit - VASDHS. Associate Program Director, PCCM Fellowship. Dr. Landsberg is a board certified internist physician who practices pulmonary and critical care medicine at the VA in San Diego.

    Dr. Landsberg has 13 years of experience and practices in Internal Medicine, Critical Care Medicine, and Pulmonary Disease. He also has a special interest in Pulmonary Hypertension.